The Expanding Role of FcRn Blockers to Achieve Minimal Symptom Expression in Patients with Generalized Myasthenia Gravis

Jan 19, 2026

- Jan 18, 2027

0.75

Claim your AMA PRA Category 1 Credit

This course is available for logged in users only. Please login or register to take the course.

Management of Patients with Non-Cystic Fibrosis Bronchiectasis: Reducing Burden of Disease...

Clinical Update on the Evolving Role of B-Cell Targeting Therapies to Improve Outcomes in ...

Beyond Symptom Control: Targeting BAFF/APRIL Pathways in Generalized Myasthenia Gravis